Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 21 microgram/actuation - inhalation, pressurised - excipient ingredients: ethanol absolute; citric acid; purified water; norflurane - atrovent metered aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with asthma and chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram/ml (equivalent: ipratropium bromide, qty 500 microgram/ml) - inhalation, conventional - excipient ingredients: sodium chloride; hydrochloric acid; purified water - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 0.261 mg/ml (equivalent: ipratropium bromide, qty 0.25 mg/ml) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; sodium chloride; hydrochloric acid; disodium edetate - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram/ml (equivalent: ipratropium bromide, qty 250 microgram/ml) - inhalation, conventional - excipient ingredients: purified water; sodium chloride; hydrochloric acid - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide 21 ug - atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. atrovent® (ipratropium bromide) nasal spray 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. atrovent® (ipratropium bromide) nasal spray 0.03% 21 mcg/spray read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip asso

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 220 ug - flovent hfa is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. important limitation of use flovent hfa is not indicated for the relief of acute bronchospasm. the use of flovent hfa is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required [see warnings and precautions (5.2)] . - hypersensitivity to any of the ingredients [see warnings and precautions (5.6), adverse reactions (6.2), description (11)] . risk summary there are insufficient data on the use of flovent hfa in pregnant women. there are clinical considerations with the use of flovent hfa in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight, and/or skeletal variations in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the m

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous - aerosol inhaler, metered dose - 20 mcg/dose - active: ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous excipient: citric acid ethanol nitrogen norflurane purified water - atrovent is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 44 ug - flovent hfa is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. limitations of use flovent hfa is not indicated for the relief of acute bronchospasm. flovent hfa is contraindicated in the following conditions: risk summary there are insufficient data on the use of flovent hfa in pregnant women. there are clinical considerations with the use of flovent hfa in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight and/or skeletal variations in rats, mice, and rabbits, was observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (mrhdid) on a mcg/m2 basis. (see data.) however, fluticasone propionate administered via inhalation to rats decreased fetal body weight but did not induce teratogenicity at a maternal toxic dose less than the mrhdid on a mcg/m2 basis.

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 100 ug - flovent diskus is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. important limitation of use flovent diskus is not indicated for the relief of acute bronchospasm. the use of flovent diskus is contraindicated in the following conditions: risk summary there are insufficient data on the use of flovent diskus in pregnant women. there are clinical considerations with the use of flovent diskus in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight, and/or skeletal variations in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (mrhdid) on a mcg/m2 basis. (see data.) however, fluticasone propionate administered via inhalation to rats decreased fetal body weight, but did not induce teratogenicity at a maternal toxic dose less than the mrhdid on